Last reviewed · How we verify
D3S-002
At a glance
| Generic name | D3S-002 |
|---|---|
| Sponsor | D3 Bio (Wuxi) Co., Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Phase 1/2 Study of D3S-002 as Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- D3S-002 CI brief — competitive landscape report
- D3S-002 updates RSS · CI watch RSS
- D3 Bio (Wuxi) Co., Ltd portfolio CI